About: Pergolide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pergolide Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. (en)
http://linked.open...generalReferences	# Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E: Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007 Jan 4;356(1):29-38. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17202453 # Breitenstein C, Korsukewitz C, Floel A, Kretzschmar T, Diederich K, Knecht S: Tonic dopaminergic stimulation impairs associative learning in healthy subjects. Neuropsychopharmacology. 2006 Nov;31(11):2552-64. Epub 2006 Jul 26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16880771 (en)
http://linked.open...gy/drugbank/group	approved (en) withdrawn (en)
http://linked.open...drugbank/halfLife	27 hours (en)
http://linked.open...ugbank/indication	Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy. (en)
sameAs	Pergolide
Title	Pergolide (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB01186/identifier/bindingdb/50017543 http://linked.opendata.cz/resource/drugbank/drug/DB01186/identifier/chemspider/43503 http://linked.opendata.cz/resource/drugbank/drug/DB01186/identifier/drugbank/DB01186 http://linked.opendata.cz/resource/drugbank/drug/DB01186/identifier/kegg-compound/C07425 http://linked.opendata.cz/resource/drugbank/drug/DB01186/identifier/national-drug-code-directory/0187-0839-01 http://linked.opendata.cz/resource/drugbank/drug/DB01186/identifier/pharmgkb/PA450873 http://linked.opendata.cz/resource/drugbank/drug/DB01186/identifier/pubchem-compound/47811 http://linked.opendata.cz/resource/drugbank/drug/DB01186/identifier/pubchem-substance/46507604 http://linked.opendata.cz/resource/drugbank/drug/DB01186/identifier/wikipedia/Pergolide
http://linked.open...mechanismOfAction	The dopamine D<sub>2</sub> receptor is a 7-transmembrane G-protein coupled receptor associated with G<sub>i</sub> proteins. In lactotrophs, stimulation of dopamine D<sub>2</sub> receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca<sup>2+</sup> from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D<sub>2</sub> receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. (en)
http://linked.open...drugbank/packager	Akorn Inc. Eli Lilly & Co. Akorn inc Amarin Pharmaceuticals Institutional Maintenance Supply Par Pharmaceuticals Pharmaceutical Utilization Management Program VA Inc. R.P. Scherer GmbH and Co. KG Novartis pharmaceuticals corp
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/5114948
http://linked.open...outeOfElimination	The major route of excretion is the kidney. (en)
http://linked.open.../drugbank/synonym	Pergolide Mesylate (en) Pergolide Methanesulfonate (en) Pergolida (en) Pergolidum (en)
http://linked.open...drugbank/toxicity	Oral, rat LD<sub>50</sub>: 15 mg/kg. Symptoms of overdose include nausea, vomiting, convulsions, decreased blood pressure, and CNS stimulation. (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/28-36-20-04
http://linked.open...k/foodInteraction	Take with food to reduce gastric irritation and nausea (en)
http://linked.open...nk/proteinBinding	90% (en)
http://linked.open...ynthesisReference	"DrugSyn.org":http://www.drugsyn.org/Pergolide.htm (en)
foaf:page	http://www.drugs.com/cdi/pergolide-mesylate.html http://www.rxlist.com/cgi/generic2/pergol.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B50E2-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B50E8-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B50E7-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B50E4-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B50E5-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B50E6-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B50E0-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B50F9-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B50DE-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B50E1-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B50DF-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Pergolide
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B50EE-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B50EF-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B50E9-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B50EA-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B50EC-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B50EB-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B50ED-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Significant amount may be absorbed (evidence on bioavailability still lacking). (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	66104-22-1 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...gbank/containedIn	Metopirone 250 mg capsule
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B50F4-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B50F6-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B50F7-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B50F8-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B50F3-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B50F2-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B50F5-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B50E3-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B50F0-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B50F1-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software